This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rojo, F. Articles by Cajal, S. R. y Search for Related Content PubMed PubMed Citation Articles by Rojo, F. Articles by Cajal, S. R. y

4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis

Authors' Affiliations: Departments of ¹ Pathology, ² Gynecology, and ³ Oncology, Vall d'Hebron University Hospital, Barcelona, Spain

Requests for reprints: Santiago Ramon y Cajal, Department of Pathology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron, 119-129 08035 Barcelona, Spain. Phone: 34-93-274-6809, ext. 6824; Fax: 34-93-274-6818; E-mail: sramon{at}vhebron.net.

Purpose: Cell signaling pathways include a complex myriad of interconnected factors from the membrane to the nucleus, such as erbB family receptors and the phosphoinositide-3-kinase/Akt/mTOR and Ras-Raf-ERK cascades, which drive proliferative signals, promote survival, and regulate protein synthesis.

Experimental Design: To find pivotal factors in these pathways, which provide prognostic information in malignancies, we studied 103 human breast tumors with an immunohistochemical profile, including total and phosphorylated (p) proteins: human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor, extracellular signal-regulated kinase 1/2, Akt, 4E-binding protein 1 (4EBP1), eukaryotic initiation factor 4E, phosphorylated ribosomal protein S6 kinase 1, phosphorylated ribosomal protein S6, and Ki67. Western blot and reverse lysate protein arrays were also done in a subset of tumors.

Results: Significantly, activation of the phosphoinositide-3-kinase/Akt/mTOR cascade was detected in a high proportion of tumors (41.9%). Tumors with HER2 overexpression showed higher p-Akt as compared with negative tumors (P < 0.001). Levels of p-Akt correlated with the downstream molecules, p-4EBP1 (P = 0.001) and p-p70S6K (P = 0.05). Although 81.5% of tumors expressed p-4EBP1, in 16.3% of these tumors, concomitant activation of the upstream factors was not detected. Interestingly, p-4EBP1 was mainly expressed in poorly differentiated tumors (P < 0.001) and correlated with tumor size (P < 0.001), presence of lymph node metastasis (P = 0.002), and locoregional recurrences (P = 0.002). Coexpression of p-4EBP1 and p-eIF4G correlated with a high tumor proliferation rate (P = 0.012).

Conclusion: In this study, p-4EBP1 was the main factor in signaling pathways that associate with prognosis and grade of malignancy in breast tumors. Moreover, p-4EBP1 was detected in both HER2-positive and HER2-negative tumors. This factor seems to be a channeling point at which different upstream oncogenic alterations converge and transmit their proliferative signal, modulating protein translation.

This article has been cited by other articles:

				P. J. Goodwin, J. A. Ligibel, and V. Stambolic Metformin in Breast Cancer: Time for Action J. Clin. Oncol., July 10, 2009; 27(20): 3271 - 3273. [Full Text] [PDF]

				C.-J. Lin, R. Sukarieh, and J. Pelletier Silibinin inhibits translation initiation: implications for anticancer therapy Mol. Cancer Ther., June 1, 2009; 8(6): 1606 - 1612. [Abstract] [Full Text] [PDF]

				J. R. Graff, B. W. Konicek, R. L. Lynch, C. A. Dumstorf, M. S. Dowless, A. M. McNulty, S. H. Parsons, L. H. Brail, B. M. Colligan, J. W. Koop, et al. eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival Cancer Res., May 1, 2009; 69(9): 3866 - 3873. [Abstract] [Full Text] [PDF]

				K. E. O'Reilly, M. Warycha, M. A. Davies, V. Rodrik, X. K. Zhou, H. Yee, D. Polsky, A. C. Pavlick, N. Rosen, N. Bhardwaj, et al. Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma Clin. Cancer Res., April 15, 2009; 15(8): 2872 - 2878. [Abstract] [Full Text] [PDF]

				A. Artero-Castro, F. B. Callejas, J. Castellvi, H. Kondoh, A. Carnero, P. J. Fernandez-Marcos, M. Serrano, S. Ramon y Cajal, and M. E. Lleonart Cold-Inducible RNA-Binding Protein Bypasses Replicative Senescence in Primary Cells through Extracellular Signal-Regulated Kinase 1 and 2 Activation Mol. Cell. Biol., April 1, 2009; 29(7): 1855 - 1868. [Abstract] [Full Text] [PDF]

				A. Jimeno, M. A. Rudek, P. Kulesza, W. W. Ma, J. Wheelhouse, A. Howard, Y. Khan, M. Zhao, H. Jacene, W. A. Messersmith, et al. Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors J. Clin. Oncol., September 1, 2008; 26(25): 4172 - 4179. [Abstract] [Full Text] [PDF]

				J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, K. Hazell, E. Martinelli, S. R. y Cajal, S. Jones, L. Vidal, et al. Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors J. Clin. Oncol., April 1, 2008; 26(10): 1603 - 1610. [Abstract] [Full Text] [PDF]

				P. Angelo, M. Anita, A. Amalia, and T. Stefania Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here? Clin. Cancer Res., October 15, 2007; 13(20): 5988 - 5990. [Full Text] [PDF]

				G. Armengol, F. Rojo, J. Castellvi, C. Iglesias, M. Cuatrecasas, B. Pons, J. Baselga, and S. Ramon y Cajal 4E-Binding Protein 1: A Key Molecular "Funnel Factor" in Human Cancer with Clinical Implications Cancer Res., August 15, 2007; 67(16): 7551 - 7555. [Abstract] [Full Text] [PDF]